INTERNATIONALISATION – FOCUS ON EMA AND FDA

Slides:



Advertisements
Similar presentations
Drugs as Medicines Coach Graner Health Class Notes.
Advertisements

VALIDATION OF COMPUTERISED SYSTEMS IN THE PHARMACEUTICAL INDUSTRY Matt Safi Product manager.
Registration and Harmonisation in the Area of Medical Products in Switzerland Swiss Russian Health Forum Basel, 10./11. September 2012 Dr. Petra Dörr Head.
The Global Generic Medications Market
Professor Stuart Walker BSc PhD MFPM FIBiol FRSC FRCPath FIstD Director CMR International UK.
Biopharmaceutical Regulatory Requirements 40. Marketing Authorization for New Chemical Entities Health Canada’s (HC) Therapeutic Products Directorate.
Pharmacologist & Toxicologist CTE Introduction. What is a Pharmacologist? Develop new drugs to cure, treat, and prevent disease. Develop new drugs to.
What is ICH? ICH is a joint initiative involving both regulators and research-based industry representatives of the EU, Japan and the US in scientific.
Biotechnology Chemical Pharmaceutical Customer Partnership
Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.
“Supporting the Industry through Communication” The pharmaceutical industry is committed to the research, development, quality manufacturing and logistics.
GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.
The association between European Medicines Agency approval and Health Technology Assessment recommendations Iga Lipska 1,2, Anke Hövels 2, Neil McAuslane.
BSC Biowaiver: Components, Requirements and Criteria
Slide 1 Encouraging innovation: the regulators perspective Bringing the best to healthcare through partnership and innovation IPHA, 1 st December 2011.
Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Anatomy of Medical Research: US and International.
I farmaci innovativi in una prospettiva europea Giuseppe M.C. Rosano, MD, PhD Cardiovascular and Cell Sciences Research Institute, St George's University.
IDMP Overview December 2015.
ICORD 2006 Kerstin Westermark Md, PhD, Assoc. prof. COMP Chairperson.
Pharmacology Science that studies interactions of drugs with organism on different levels (subcellular, cellular, organ, systemic) Studies: - relationship.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Mammalian Cells Bioreactor Market to reach $1.5 bn by 2024
Regulatory Updates Health Sciences Authority Singapore
Contingent Workforce: Cerner Quality System & Regulations
Security Research Institute
Going Global Vincent J. Amoruccio, M.A. How Data Standards
Figure 3. BLA and NME Drugs Sponsored by US companies ( )
Presentation on Good Manufacturing Practice
Biotechnology Chemical Pharmaceutical Customer Partnership
The percentage of NASs approved by CDER
NASs approval time by therapeutic area:
Median 25th and 75th percentile
Prescription for Pharmaceutical Reform: Healing an Ailing System
Median approval time for new active substances approved by ICH agencies by approval year Methodology For each new active substance (NAS) approved between.
What is ICH? ICH is a joint initiative involving both regulators and research-based industry representatives of the EU, Japan and the US in scientific.
Introduction to Pharmacology: Drug Regulation and Approval Chapter 1
Comparing HTA recommendations
, R&D expenditure showed 6% growth annually
Percentage Key Message
2002–2006 Mid and Other sized companies continued to launch the majority of NMEs APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON.
Median submission gap, median approval time and percentage approved as expedited for new active substances (NASs) approved by six authorities:
Median time to internationalisation
Comparison of median time for submission to EM countries from 1st world-wide approval ( vs ) Median time from 1st WW approval to submission.
New active substance median approval time for six regulatory authorities in Key messages The last decade, , saw a continuation.
Comparison of median approval time of NASs by year of submission vs
New active substances approved by EMA and FDA over 10 years
EMA: The European Medicines Agency
From Regulatory Approval to Subsidized Patient Access in the Asia-Pacific Region: A Comparison of Systems Across Australia, China, Japan, Korea, New Zealand,
“Metro Map” analysis of FDA facilitated regulatory pathways and their influence on median approval times  The US Food and Drug Administration (FDA) has.
Professional Organizations
Building quality in HTA process and decision making
NME/NAS launches in 2005/6 APRIL 2007
Fundamentals of Electronic Submissions and eCTD
Rollout time breakdown: 24 common NASs in 7 jurisdictions
Pipeline size of Major companies had grown at a steadier rate than that of smaller companies APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
Development time for new molecular entities first launched onto the world market between MARCH 2008 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS.
Cycle times decreased in larger but not smaller, companies
PRISMA study flow diagram
Opening an IND: Investigator Perspective
Median, Box : 25th and 75th percentiles
Assessment routes and timelines in Australia (2011)
Comparison of median approval time of NASs by year of submission vs
Assessment of quality decision making in regulatory agencies and pharmaceutical companies with QoDoS (Quality of Decision Making Orientation Scheme) Not.
Introduction to Basic Research Methods
Out of the 52 NASs approved by all six authorities during :
Median times to submission and licensing for 70 new active substances approved in five markets from 1997 to 2010 Note: EMA approval.
Assessment routes and timelines
Public Health Services
Global Nutraceuticals Market
Comparison of median time for submission to EM countries from 1st world-wide approval ( vs ) Median time from 1st WW approval to submission.
Global Specialty Pharmaceuticals Market. Report Description and Highlights According to Renub Research report "Specialty Pharmaceuticals Market, by Country.
Presentation transcript:

INTERNATIONALISATION – FOCUS ON EMA AND FDA In 2012-2014, there were 118 NASs approved either by EMA or FDA or both 7 NASs approved only by EMA 81 NASs approved by EMA and FDA 30 NASs approved only by FDA These were internationalised in PMDA, Health Canada, Swissmedic and TGA as follows (approval status tracked until the end of 2016) 81 approved by EMA and FDA 50 approved X 31 not approved 67 approved X 14 not approved 68 approved X 13 not approved 65 approved X 16 not approved Methodology New active substances (NASs) approved initially in 2012-2014 by either the European Medicines Agency (EMA) centralised procedure (N=7) or the United States Food and Drug Administration (FDA) (N=30) or both (N=81) were identified. The approval status was tracked for those NASs in Japan Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, Swissmedic and the Australian Therapeutic Goods Administration (TGA) until the end of 2016. Key messages Not all NASs approved in 2012-2014 by EMA, FDA or both received approval in the other 4 regulatory agencies (PMDA, Health Canada, Swissmedic and TGA) by the end of 2016. There were more products only approved in FDA (30) as opposed to only EMA (7), but the biggest group of NASs were approved by both EMA and FDA (81). For the 81 NASs approved by both EMA and FDA, 84% were approved by Swissmedic, followed by Health Canada (83%), TGA (80%) and PMDA (62%). For the 30 NASs only approved by FDA, 27% were approved by Health Canada, followed by PMDA (23%), TGA (20%) and Swissmedic (10%). For the 7 NASs only approved by EMA, 43% were approved by TGA, followed by PMDA (29%), Swissmedic (29%) and Health Canada (14%). In general, NASs from a top companies (R&D budget> 3 billion USD in 2016) initially approved by EMA and FDA, had a higher proportion of approval in the other 4 agencies (~50-60%), compared with those approved by non-top companies (~20-30%). Definitions New active substance (NAS): A chemical, biological, biotechnology or radiopharmaceutical substance that has not been previously available for therapeutic use in humans and is destined to be made available as a ‘prescription only medicine’, to be used for the cure, alleviation, treatment, prevention or in vivo diagnosis of diseases in humans; Approval time: Time calculated from the date of submission to the date of approval by the agency (calendar days). This time includes agency and company time; Top company: Pharmaceutical company with R&D spending>3 billion USD in 2016 (http://www.pharmexec. com/2016-pharm -exec-50). From: Bujar M, McAuslane N, Liberti L. 2017. R&D Briefing 65: New drug approvals in six major authorities 2007 – 2016: Focus on the internationalisation of medicines. Centre for Innovation in Regulatory Science. London, UK. For more trends and analysis, please download the full CIRS R&D Briefing 65: http://www.cirsci.org/wp-content/uploads/2017/11/CIRS-RD-Briefing-65-20112017.pdf 30 approved only by FDA 7 approved X 23 not approved 8 approved X 22 not approved 3 approved X 27 not approved 6 approved X 24 not approved 7 approved only by EMA 2 approved X 5 not approved 1 approved X 6 not approved 2 approved X 5 not approved 3 approved X 4 not approved Health Canada PMDA Swissmedic TGA © CIRS, R&D Briefing 65